QNTA - QNTA STOCK NEWS

Medolife Rx, majority-owned by Quanta, Inc. (OTC PINK: QNTA), has announced the cancellation of a proposed reverse stock split included in a recent 14C filing. The decision, reached after consulting legal counsel, aims to protect shareholder interests. The company emphasizes its commitment to transparency and shareholder engagement, highlighted by a recent investor webcast. Medolife is focused on developing innovative biotechnology products, leveraging proprietary polarization technology.

Medolife Rx, Inc., a biotechnology company and subsidiary of Quanta, Inc. (OTC PINK: QNTA), will host a live webcast on July 27, 2021, at 5 PM EDT. The event aims to address investor questions during an open forum led by CEO Dr. Arthur Mikaelian. Key topics include updates on social media engagement, investor relations, share overview, Nasdaq status, and progress with Escozine®, a potential treatment for COVID-19 and cancer. Participants can register via the provided link, and a recording will be available post-event.

Medolife Rx, a subsidiary of Quanta (QNTA), has announced a donation of its lead drug candidate, Escozine®, to the Cruz Jiminian Foundation in the Dominican Republic to aid COVID-19 patients. Escozine® is recently registered as a natural alternative medicine and aims to provide palliative care for COVID-19. Preliminary studies indicate its safety and potential effectiveness. Additionally, the company plans to pursue FDA approval while conducting further studies to assess the drug's ability to mitigate vaccine side effects.

Medolife Rx, a subsidiary of Quanta (OTC PINK: QNTA), announced promising clinical observations regarding its leading drug candidate, Escozine®. Patients experiencing adverse reactions from COVID-19 vaccines reported significantly reduced side effects after taking Escozine®. This has prompted the company to initiate additional pilot studies aimed at evidencing Escozine®'s efficacy in alleviating vaccine side effects. The drug, which contains scorpion peptides, is already pursuing regulatory approval in multiple regions, including the US and Dominican Republic.

Medolife Rx, a subsidiary of Quanta, Inc. (QNTA), has completed a stability study of its drug candidate Escozine®, which was conjugated with radioactive iodine, demonstrating strong stability. This study supports the upcoming Pharmacokinetic (PK) study required by the FDA as part of its Pre-IND submission for COVID-19. The conjugation allows better visualization of how Escozine® is processed in the body, with potential applications in diagnostics. Medolife aims to utilize the stability findings for further exploration of Escozine® in both therapeutic and diagnostic contexts.

Medolife Rx, a subsidiary of Quanta (OTC PINK: QNTA), has partnered with Xoles Del Pacifico to distribute its wellness products in Mexico. The deal includes Medolife’s Immunapen™ product line and CBD pain relief creams, leveraging Xoles' extensive retail network. The Mexican market offers a less saturated environment for Medolife, presenting significant growth opportunities. Medolife aims to tap into rising consumer demand for wellness products post-COVID-19 and expand its global footprint while retaining U.S. marketing rights.

Medolife Rx, a subsidiary of Quanta (OTC PINK: QNTA), received a positive FDA response regarding its Pre-IND filing for the COVID-19 treatment, Escozine®. The FDA recognized the clinical trial in the Dominican Republic as a proof-of-concept study and provided specific guidelines for further development. To proceed, Medolife must conduct two additional toxicology studies focusing on DNA-level impacts. The FDA's detailed roadmap aims to expedite future U.S. clinical trials, enhancing the likelihood of Escozine's approval as an effective therapeutic option against COVID-19.

Medolife Rx, a subsidiary of Quanta (OTC PINK: QNTA), announced a brand endorsement deal with skateboard legend Tony Hawk to promote its new Aelia line of polarized CBD products. These products leverage patented polarization technology, enhancing effectiveness over 500% compared to non-polarized alternatives. The rebranded Aelia line includes existing and new formulations aimed at pain relief, wound care, stress relief, and sun care. The partnership targets a broad audience, from elite athletes to everyday users seeking effective relief.

Medolife Rx, a subsidiary of Quanta, Inc. (OTC PINK: QNTA), has addressed shareholders in a statement instead of a scheduled webcast on June 8, 2021. The company provided updates on its pre-IND submission with the FDA, anticipating a response by mid-June. Medolife is also launching a new nutraceutical brand named Aelia, featuring patented polarization technology. Additionally, a recent SEC filing indicated plans for increasing the number of authorized shares and potentially executing a reverse split. The company has over $600,000 in outstanding convertible debt and is focused on transitioning to more prominent exchanges.